BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

522 related articles for article (PubMed ID: 26515260)

  • 1. Nanoparticle therapeutics: Technologies and methods for overcoming cancer.
    Cerqueira BB; Lasham A; Shelling AN; Al-Kassas R
    Eur J Pharm Biopharm; 2015 Nov; 97(Pt A):140-51. PubMed ID: 26515260
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Nanoparticle approaches to combating drug resistance.
    Moon JH; Moxley JW; Zhang P; Cui H
    Future Med Chem; 2015 Aug; 7(12):1503-10. PubMed ID: 26334205
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Nanomedicine for targeted cancer therapy: towards the overcoming of drug resistance.
    Shapira A; Livney YD; Broxterman HJ; Assaraf YG
    Drug Resist Updat; 2011 Jun; 14(3):150-63. PubMed ID: 21330184
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Role of integrated cancer nanomedicine in overcoming drug resistance.
    Iyer AK; Singh A; Ganta S; Amiji MM
    Adv Drug Deliv Rev; 2013 Nov; 65(13-14):1784-802. PubMed ID: 23880506
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Progress in the study of drug delivery system based on nanoparticles to overcome multi-drug resistance].
    Chen JN; Shen Q; Li SS
    Yao Xue Xue Bao; 2009 Apr; 44(4):333-7. PubMed ID: 19545047
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Cancer multidrug resistance: mechanisms involved and strategies for circumvention using a drug delivery system.
    Kibria G; Hatakeyama H; Harashima H
    Arch Pharm Res; 2014 Jan; 37(1):4-15. PubMed ID: 24272889
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Nano-based strategies to overcome p-glycoprotein-mediated drug resistance.
    Niazi M; Zakeri-Milani P; Najafi Hajivar S; Soleymani Goloujeh M; Ghobakhlou N; Shahbazi Mojarrad J; Valizadeh H
    Expert Opin Drug Metab Toxicol; 2016 Sep; 12(9):1021-33. PubMed ID: 27267126
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Advanced targeted therapies in cancer: Drug nanocarriers, the future of chemotherapy.
    Pérez-Herrero E; Fernández-Medarde A
    Eur J Pharm Biopharm; 2015 Jun; 93():52-79. PubMed ID: 25813885
    [TBL] [Abstract][Full Text] [Related]  

  • 9. The achievement of ligand-functionalized organic/polymeric nanoparticles for treating multidrug resistant cancer.
    Lee WH; Loo CY; Leong CR; Young PM; Traini D; Rohanizadeh R
    Expert Opin Drug Deliv; 2017 Aug; 14(8):937-957. PubMed ID: 27759437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Revisiting the role of nanoparticles as modulators of drug resistance and metabolism in cancer.
    Gupta P; Jani KA; Yang DH; Sadoqi M; Squillante E; Chen ZS
    Expert Opin Drug Metab Toxicol; 2016; 12(3):281-9. PubMed ID: 26799671
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Multifunctional and multitargeted nanoparticles for drug delivery to overcome barriers of drug resistance in human cancers.
    Dawar S; Singh N; Kanwar RK; Kennedy RL; Veedu RN; Zhou SF; Krishnakumar S; Hazra S; Sasidharan S; Duan W; Kanwar JR
    Drug Discov Today; 2013 Dec; 18(23-24):1292-300. PubMed ID: 24055842
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Liposomes and nanoparticles: nanosized vehicles for drug delivery in cancer.
    Malam Y; Loizidou M; Seifalian AM
    Trends Pharmacol Sci; 2009 Nov; 30(11):592-9. PubMed ID: 19837467
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Nanotechnology applied to overcome tumor drug resistance.
    Gao Z; Zhang L; Sun Y
    J Control Release; 2012 Aug; 162(1):45-55. PubMed ID: 22698943
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Targeted nanomedicine for cancer therapeutics: Towards precision medicine overcoming drug resistance.
    Bar-Zeev M; Livney YD; Assaraf YG
    Drug Resist Updat; 2017 Mar; 31():15-30. PubMed ID: 28867241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. [Progress in the study of micelle delivery system reversing multidrug resistance].
    Diao YY; Han M; Chen DW; Gao JQ
    Yao Xue Xue Bao; 2009 Jul; 44(7):710-5. PubMed ID: 19806907
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Overcoming cancer multidrug resistance by codelivery of doxorubicin and verapamil with hydrogel nanoparticles.
    Qin M; Lee YE; Ray A; Kopelman R
    Macromol Biosci; 2014 Aug; 14(8):1106-15. PubMed ID: 24771682
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Overcoming multidrug resistance with nanomedicines.
    Ganoth A; Merimi KC; Peer D
    Expert Opin Drug Deliv; 2015 Feb; 12(2):223-38. PubMed ID: 25224685
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Anti-P-glycoprotein conjugated nanoparticles for targeting drug delivery in cancer treatment.
    Iangcharoen P; Punfa W; Yodkeeree S; Kasinrerk W; Ampasavate C; Anuchapreeda S; Limtrakul P
    Arch Pharm Res; 2011 Oct; 34(10):1679-89. PubMed ID: 22076768
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Update on Nanotechnology-based Drug Delivery Systems in Cancer Treatment.
    Ho BN; Pfeffer CM; Singh ATK
    Anticancer Res; 2017 Nov; 37(11):5975-5981. PubMed ID: 29061776
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Nanoparticle and targeted systems for cancer therapy.
    Brannon-Peppas L; Blanchette JO
    Adv Drug Deliv Rev; 2004 Sep; 56(11):1649-59. PubMed ID: 15350294
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 27.